Indivior Granted Temporary Restraining Order on Generic Sublingual Film

Indivior PLC (LON: INDV) (“Indivior” or the “Company”) today announced that the U.S. District Court for the District of New Jersey has granted Indivior a temporary restraining order (TRO) that prevents Alvogen Pine Brook LLC (Alvogen) from launching its generic buprenorphine and naloxone sublingual film product.

This TRO will remain in place until February 7, 2019.

A Preliminary Injunction (PI) hearing will take place on that day.

“We are pleased that the District of New Jersey has granted Indivior’s motion for a TRO,” said Shaun Thaxter, CEO of Indivior. “We will continue to vigorously pursue our infringement cases against Alvogen to protect our SUBOXONE(R) (buprenorphine and naloxone) Sublingual Film patent portfolio, including continuing to pursue the appeal of the U.S. District Court for the District of Delaware’s non-infringement decision related to U.S. patents 8,603,514, as well as litigating our recently listed Orange Book patents for SUBOXONE(R) Film.”

https://www.marketscreener.com/INDIVIOR-19344116/news/Indivior-Is-Granted-Temporary-Restraining-Order-on-Generic-Sublingual-Film-27922447/